Matters Arising: Immortal time bias in the analysis of drug prescription trajectories

Research output: Contribution to journal › Comment/debate › Research › peer-review

Standard

Matters Arising : Immortal time bias in the analysis of drug prescription trajectories. / Christensen, Daniel Mølager; Gislason, Gunnar; Gerds, Thomas.

In: npj Digital Medicine, Vol. 5, No. 1, 190, 2022.

Research output: Contribution to journal › Comment/debate › Research › peer-review

Harvard

Christensen, DM, Gislason, G & Gerds, T 2022, 'Matters Arising: Immortal time bias in the analysis of drug prescription trajectories', npj Digital Medicine, vol. 5, no. 1, 190. https://doi.org/10.1038/s41746-022-00722-6

APA

Christensen, D. M., Gislason, G., & Gerds, T. (2022). Matters Arising: Immortal time bias in the analysis of drug prescription trajectories. npj Digital Medicine, 5(1), [190]. https://doi.org/10.1038/s41746-022-00722-6

Vancouver

Christensen DM, Gislason G, Gerds T. Matters Arising: Immortal time bias in the analysis of drug prescription trajectories. npj Digital Medicine. 2022;5(1). 190. https://doi.org/10.1038/s41746-022-00722-6

Author

Christensen, Daniel Mølager ; Gislason, Gunnar ; Gerds, Thomas. / Matters Arising : Immortal time bias in the analysis of drug prescription trajectories. In: npj Digital Medicine. 2022 ; Vol. 5, No. 1.

Bibtex

@article{6862218f30054b4aa7d701f513419797,
title = "Matters Arising: Immortal time bias in the analysis of drug prescription trajectories",
abstract = "Aguayo-Orozco et al. [1] report survival differences in patients taking renin-angiotensin system inhibitors depending on the drug prescription trajectories identified through Danish healthcare registries. They found that changing from an initial prescription of an ACE (angiotensin-converting enzyme) inhibitor to an angiotensin receptor blocker (ARB) and vice versa conferred a survival benefit compared to no change using standard statistical tools for survival analysis. They replicated this finding in data from the UK Biobank and concluded that their results may be important when updating treatment guidelines",
author = "Christensen, {Daniel M{\o}lager} and Gunnar Gislason and Thomas Gerds",
year = "2022",
doi = "10.1038/s41746-022-00722-6",
language = "English",
volume = "5",
journal = "npj Digital Medicine",
issn = "2398-6352",
publisher = "Nature Publishing Group",
number = "1",

}

RIS

TY - JOUR

T1 - Matters Arising

T2 - Immortal time bias in the analysis of drug prescription trajectories

AU - Christensen, Daniel Mølager

AU - Gislason, Gunnar

AU - Gerds, Thomas

PY - 2022

Y1 - 2022

N2 - Aguayo-Orozco et al. [1] report survival differences in patients taking renin-angiotensin system inhibitors depending on the drug prescription trajectories identified through Danish healthcare registries. They found that changing from an initial prescription of an ACE (angiotensin-converting enzyme) inhibitor to an angiotensin receptor blocker (ARB) and vice versa conferred a survival benefit compared to no change using standard statistical tools for survival analysis. They replicated this finding in data from the UK Biobank and concluded that their results may be important when updating treatment guidelines

AB - Aguayo-Orozco et al. [1] report survival differences in patients taking renin-angiotensin system inhibitors depending on the drug prescription trajectories identified through Danish healthcare registries. They found that changing from an initial prescription of an ACE (angiotensin-converting enzyme) inhibitor to an angiotensin receptor blocker (ARB) and vice versa conferred a survival benefit compared to no change using standard statistical tools for survival analysis. They replicated this finding in data from the UK Biobank and concluded that their results may be important when updating treatment guidelines

U2 - 10.1038/s41746-022-00722-6

DO - 10.1038/s41746-022-00722-6

M3 - Comment/debate

C2 - 36813918

AN - SCOPUS:85145371141

VL - 5

JO - npj Digital Medicine

JF - npj Digital Medicine

SN - 2398-6352

IS - 1

M1 - 190

ER -

ID: 332198387